Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.65 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.50 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.50 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.50 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.50 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.50 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.50 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.50 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.50 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.50 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.50 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.50 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776764 | 0.89 | GPR119 (0.69) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL29749146 | 0.86 | GPR119 (0.66) | GPR119NPBWR1MCHR1 | |
| SCHEMBL20137646 | 0.86 | GPR119 (0.66) | GPR119NPBWR1MCHR1 | |
| SCHEMBL30201512 | 0.85 | GPR119 (0.65) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL17654170 | 0.85 | GPR119 (0.65) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL20920037 | 0.85 | GPR119 (0.49) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL2776282 | 0.84 | GPR119 (0.64) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3343917 | 0.84 | GPR119 (0.64) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL23545074 | 0.83 | GPR119 (0.47) | GPR119CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL20936756 | 0.83 | GPR119 (0.47) | GPR119CACNB4CACNA1ACACNA1GCACNG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642773-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642535-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025048557-A1 | COMPOUND FOR DEGRADING ANDROGEN RECEPTOR AND MEDICAL USE THEREOF | 주식회사 유빅스테라퓨틱스 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024141444-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141443-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024141443-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS SIK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| CN-116406360-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4204415-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-11013724-B2 | Glutaminase inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-05-25 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1347990-B1 | Peptides having inhibiting activity to nitric oxyde production | ASTELLAS PHARMA INC (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7129243-B2 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | CDK4, CDKL4, CDK2 | GPR119 3465/4885CACNB4 4476/4885CACNA1A 4349/4885 |
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | GPR119 118/4885CACNB4 3411/4885CACNA1A 2911/4885 |
| US-11013724-B2 | Glutaminase inhibitors | GLUL, ASNS, GLS | GPR119 477/4885CACNB4 3602/4885CACNA1A 2067/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | GPR119 3465/4885CACNB4 4476/4885CACNA1A 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.